Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Raising 2025 NERLYNX® revenue and net income estimates
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...